August 18, 2017 – Ringwood, NJ – The Pharma & Biopharma Outsourcing Association (PBOA), a trade group that represents Contract Manufacturing Organizations (CMOs) and other service providers in the bio/pharmaceutical sector, is pleased that H.R. 2430, the FDA Reauthorization Act (FDARA), has been signed into law, renewing four major user fee agreements between industry and FDA for FY2018 to FY2022.
PBOA president Gil Roth issued the following statement:
“A year ago, industry ratified the second iteration of Generic Drug User Fee Amendments (GDUFA II), and today I commend the White House for signing it into law via FDARA. GDUFA II will empower FDA and industry to work toward swifter approval of cost-lowering generic drugs.
“One of PBOA’s key goals was to bring CMOs to the table to help develop a fairer fee structure that better reflects the economic models of the various stakeholders. PBOA worked extensively with FDA and our industry partners to achieve that goal, and we are happy that GDUFA — along with its Prescription, Biosimilar, and Medical Device counterparts — has been authorized for a new five-year term.
“PBOA applauds the bipartisan efforts of the Senate Health, Education, Labor and Pension (HELP) Committee and House Energy and Commerce Committee to bring FDARA through Congress, and we look forward to working with FDA and our peers to bring safe, effective medicines to patients.”
About the PBOA
Founded in 2014, the Pharma & Biopharma Outsourcing Association (PBOA) is a nonprofit trade association dedicated to advancing the regulatory, legislative and general business interests of Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs). PBOA members provide the services that help the pharma and biopharma industry develop and manufacture drugs, biologics, vaccines, and other treatments safely and cost effectively. For more information about the PBOA, its members, and its mission, please visit www.pharma-bio.org. Follow PBOA on Twitter at @PBOAssoc.
For more information:
Gil Roth
President, PBOA
gil.roth@pharma-bio.org
201-788-7994
